SCHEMBL25546375

SCHEMBL25546375

CCc1ccc(-c2nc(Cl)sc2CC(C)C)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.44
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
S1PR1 P21453 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
GRM2 Q14416 2/20 0.36
POLB P06746 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 1/20 0.33
PGK1 P00558 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25545941 0.88 LMNA (0.48) FBP1MAPTLMNAS1PR1POLB
SCHEMBL25557118 0.87 LMNA (0.54) FBP1MAPTLMNAS1PR1TAAR1
SCHEMBL25545932 0.86 FBP1 (0.44) FBP1MAPTLMNAS1PR1GRM2
SCHEMBL25546325 0.85 S1PR1 (0.50) FBP1MAPTLMNAS1PR1ALDH1A1
SCHEMBL25545928 0.84 FBP1 (0.42) FBP1MAPTLMNAS1PR1GRM2
SCHEMBL25545925 0.82 ALDH1A1 (0.42) FBP1MAPTLMNAS1PR1ALDH1A1
SCHEMBL25546030 0.80 FBP1 (0.42) FBP1MAPTLMNAS1PR1GRM2
SCHEMBL25546019 0.78 FBP1 (0.41) FBP1MAPTLMNAS1PR1GRM2
SCHEMBL25183737 0.77 FBP1 (0.45) FBP1MAPTPOLBALDH1A1MEN1
SCHEMBL18282312 0.77 FBP1 (0.48) FBP1MAPTLMNAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FBP1 735/4885MAPT 2231/4885LMNA 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.